Development Pipeline

This is the development pipeline as of Jul. 21, 2023

1. Oncology

As of Jul. 21, 2023

Product Name/
Development Code/
Generic Name
Mechanism Dosage Form Target Indication Phase* Area Licensor
F
Opdivo
Intravenous
Infusion
Anti-PD-1 antibody Injection Malignant mesothelioma(Excluding Pleura)
 
 
 
 
 
JP In-house
(Co-developed with BMS)
Epithelial skin malignancies
 
 
 
 
 
JP
Hepatocellular carcinoma
 
 
 
 
 
JP・KR
Ovarian cancer
 
 
 
 
 
JP・KR・TW
Bladder cancer
 
 
 
 
 
JP・KR・TW
Metastatic castration sensitive prostate cancer
 
 
 
 
 
JP・KR・TW
Braftovi
Capsules
BRAF inhibitor Capsule Thyroid cancer
 
 
 
 
 
JP Pfizer
Mektovi
Tablets
MEK inhibitor Tablet Thyroid cancer
 
 
 
 
 
JP Pfizer
Yervoy
Injection★
Anti-CTLA-4 antibody Injection Gastric cancer
 
 
 
 
 
JP・KR・TW BMS
Urothelial cancer
 
 
 
 
 
JP・KR・TW
Hepatocellular carcinoma
 
 
 
 
 
JP・KR
ONO-7913/
Magrolimab
Anti-CD47 antibody Injection TP53-mutant Acute myeloid leukemia
 
 
 
 
 
JP Gilead
Acute myeloid leukemia
 
 
 
 
 
KR・TW
Pancreatic cancer★
 
 
 
 
 
JP
Colorectal cancer★
 
 
 
 
 
JP
Solid tumor
 
 
 
 
 
JP
Myelodysplastic syndrome
 
 
 
 
 
JP
ONO-4686★ Anti-TIGIT antibody Injection Solid tumor
 
 
 
 
 
JP BMS
ONO-4482★/
Relatlimab
Anti-LAG-3 antibody Injection Melanoma
 
 
 
 
 
JP BMS
ONO-7226★ Anti-ILT4 antibody Injection Solid tumor
 
 
 
 
 
JP BMS
ONO-7475/
Tamnorzatinib
Axl/Mer inhibitor Tablet Solid tumor★
 
 
 
 
 
JP In-house
EGFR-mutated non-small cell lung cancer
 
 
 
 
 
JP
ONO-4578 PG receptor (EP4) antagonist Tablet Colorectal cancer★
 
 
 
 
 
JP In-house
Pancreatic cancer★
 
 
 
 
 
JP
Non-small cell lung cancer★
 
 
 
 
 
JP
Solid tumor・Gastric cancer★
 
 
 
 
 
JP
Hormone receptor-positive, HER2-negative breast cancer
 
 
 
 
 
JP
ONO-7119★/
Atamparib
PARP7 inhibitor Tablet Solid tumor
 
 
 
 
 
JP Ribon
ONO-7122★ TGF-β inhibitor Injection Solid tumor
 
 
 
 
 
JP BMS
ONO-7914★ STING agonist Injection Solid tumor
 
 
 
 
 
JP In-house
ONO-4059 Bruton‘s tyrosine kinase (BTK) inhibitor Tablet Primary central nervous system lymphoma
 
 
 
 
 
US In-house
ONO-4685 PD-1×CD3 bispecific antibody Injection T-cell lymphoma
 
 
 
 
 
US In-house
ONO-7018 MALT1 inhibitor Tablet Non-Hodgkin lymphoma, Chronic lymphocytic leukemia
 
 
 
 
 
US Chordia

★Combination with Opdivo.

※In the case of clinical development of the oncology drugs in the same indication, the most advanced clinical phase is described.

  • Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed

2. Areas other than Oncology

As of Jul. 21, 2023

Product Name/
Development Code/
Generic Name
Mechanism Dosage Form Target Indication Phase* Area Licensor
F
Velexbru Tablets/
Tirabrutinib
Hydrochloride
Bruton‘s tyrosine kinase (BTK) inhibitor Tablet Pemphigus
 
 
 
 
 
JP In-house
ONO-2017/
Cenobamate
Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABAA ion channel Tablet Primary generalized tonic-clonic seizures
 
 
 
 
 
JP SKBP
Partial-onset seizures
 
 
 
 
 
JP
ONO-2910 Enhancement of Schwann cell differentiation Tablet Diabetic polyneuropathy
 
 
 
 
 
JP In-house
Chemotherapy-Induced Peripheral Neuropathy
 
 
 
 
 
JP
ONO-2808 S1P5 receptor agonist Tablet Multiple System Atrophy
 
 
 
 
 
US In-house
ONO-4685 PD-1×CD3 bispecific antibody Injection Autoimmune disease
 
 
 
 
 
JP・EU In-house
ONO-7684 FXIa Inhibitor Tablet Thrombosis
 
 
 
 
 
JP・EU In-house
ONO-2020 Epigenetic Regulation Tablet Neurodegenerative disease
 
 
 
 
 
US In-house
ONO-1110 Endocannabinoid regulation Oral Pain
 
 
 
 
 
JP In-house
  • Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed